Our portfolio

Tuberculosis diagnostic development

Ustar Biotechnologies, a diagnostics company, is developing a tuberculosis diagnostic to increase prevention against one of the leading causes of death worldwide.
Website
  • Domain
    Life Sciences
  • Investment type
    Direct equity
  • Status
    Exit
  • Initial investment
    Series C
  • Partnered in
    2014
  • Investment lead
    Chris Chen
  • Headquarters
    China
  • Program strategy
    Diagnostics

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.